📄 medicine

Increased frequency of non-aeruginosa Pseudomonas species isolation from the airways of people with cystic fibrosis after initiating Elexacaftor/Tezacaftor/Ivacaftor treatment

A retrospective study of 417 Italian cystic fibrosis patients revealed a significant increase in the isolation of non-aeruginosa Pseudomonas species from airways following the initiation of elexacaftor/tezacaftor/ivacaftor (ETI) treatment, suggesting that ETI may alter the airway microbiota and necessitating further research into the clinical implications of these findings.

Original authors: Silvia Campana, Daniela Dolce, Roberto Caporale, Pamela Vitullo, Maria Cristina Lucanto, Vito Terlizzi

Published 2026-08-11

📖 3 min read☕ Coffee break read

CC BY 4.0

Original authors: Silvia Campana, Daniela Dolce, Roberto Caporale, Pamela Vitullo, Maria Cristina Lucanto, Vito Terlizzi

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine your lungs as a bustling, high-tech city. In a healthy city, the airways are wide, clean streets where oxygen flows freely, and the "police force" (your immune system) keeps things orderly. But for people with cystic fibrosis (CF), the city's sanitation system is broken. A thick, sticky goo clogs the streets, creating a perfect hiding spot for troublemakers—bacteria that love to set up camp in the mucus. For years, the biggest villain in this city was a notorious gang leader called Pseudomonas aeruginosa.

Enter the "Super Repair Crew," a new type of medicine called ETI (elexacaftor/tezacaftor/ivacaftor). Think of ETI as a master key that fixes the broken sanitation pipes, thinning out the goo and letting the city breathe again. This has been a game-changer, making life much better for many. But here's the twist: when you fix a city's infrastructure, you don't just kick out the old bad guys; you might accidentally change the neighborhood so much that new kinds of troublemakers show up. Scientists have been watching closely to see if fixing the pipes changes the bacterial "neighborhood" in unexpected ways, specifically looking for a whole family of cousins to the main villain: the non-aeruginosa Pseudomonas species.

This paper is a detective story about what happened when 417 people with cystic fibrosis in Italy started using the ETI "Super Repair Crew." The researchers looked at the bacterial "report cards" (respiratory cultures) from these patients for one year before they took the medicine and one year after. They were hunting for a specific group of bacteria called non-aeruginosa Pseudomonas species (NAPs). Before the treatment, finding these specific bacteria was as rare as spotting a unicorn; only one patient out of the whole group had them. But after the treatment started, the story changed dramatically.

The results showed that 20 out of the 417 patients (about 4.8%) suddenly had these NAPs showing up in their airways. That's a huge jump compared to before. The researchers found 15 different types of these bacteria, mostly belonging to groups known as P. fluorescens and P. putida. It's as if the city, once cleaned up by the new medicine, suddenly became a popular hangout spot for a whole new crew of bacteria that used to be rare visitors. The team found that, on average, these new bacteria showed up about 5 months after the patients started the treatment.

The authors suggest that the medicine might be reshaping the airway environment so much that it allows these specific bacteria to thrive where they couldn't before. However, they are very careful not to say this is a disaster or a new "bad guy" problem yet. They point out that we don't know if these new bacteria actually make people sicker or if they are just harmless guests enjoying the cleaner air. Because we don't have the full story on whether these bacteria need to be fought with antibiotics, the paper suggests that doctors should keep a close watch on patients. The goal is to make sure we don't start spraying antibiotics on a city that is actually doing just fine, just because a few new, unknown faces moved in. This study is the largest look so far at this specific phenomenon, suggesting that while the medicine is a hero, it might be rewriting the rules of the bacterial neighborhood in ways we are just beginning to understand.

Technical Summary: Increased Frequency of Non-Aeruginosa Pseudomonas Species Post-ETI Therapy

Problem Statement
The introduction of the CFTR modulator elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved clinical outcomes and quality of life for people with cystic fibrosis (pwCF). While the impact of ETI on major CF pathogens, particularly Pseudomonas aeruginosa, is well-documented, its effect on other bacterial species remains poorly understood. Specifically, there is a lack of data regarding the incidence of non-aeruginosa Pseudomonas species (NAPs) in the airways of pwCF following the initiation of ETI therapy. This study addresses the gap in knowledge concerning whether ETI alters the airway microbiota to favor the detection of these less common Pseudomonas species.

Methodology
This retrospective study analyzed respiratory cultures from 417 pwCF attending three Italian Cystic Fibrosis centers. The study population included individuals carrying at least one F508del allele, for whom ETI was licensed in Italy starting July 2021.

Data Collection: Microbiological data were extracted from routine respiratory cultures collected during the year prior to ETI initiation and the year following initiation.
Sample Types: The analysis included oropharyngeal swabs and sputum specimens.
Identification: Bacterial isolates were identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF).
Statistical Analysis: Fisher's exact test was employed to compare the incidence of NAPs-positive cultures before and after treatment.
Ethical Compliance: The study adhered to the Declaration of Helsinki, received approval from the Ethics Committee for Paediatric Clinical Trials in Florence (No. 47/2024), and obtained informed consent from all participants or their guardians.

Key Results
The study observed a statistically significant increase in the isolation of NAPs following the initiation of ETI therapy:

Incidence: In the pre-ETI period, only one patient (out of 62 samples) tested positive for NAPs. In the post-ETI period, 20 patients (4.79% of the 417 cohort) had at least one NAPs-positive culture (out of 74 samples). This difference was statistically significant ( $p < 0.001$ ).
Timing: The mean time to the first detection of a NAPs species after starting ETI was 5 months (IQR 9).
Species Diversity: Fifteen different NAPs species were identified. The majority of isolates belonged to the Pseudomonas fluorescens group (including P. fluorescens, P. koreensis, P. tolaasii, P. gessardi, P. mucidolens, P. proteolitica, P. rhodesiae, P. azotoformans, and P. libanensis) and the P. putida group (including P. monteilii, P. putida, P. orizihabitans, and P. plecoglossicida). Other identified species included P. chlororaphis and P. alcaligenes.
Co-isolation: In two instances, two different NAPs species were isolated simultaneously from the same sample.

Key Contributions

Documentation of Emergence: This study provides the largest case series to date describing the emergence of NAPs in pwCF following ETI therapy, contrasting sharply with the pre-modulator era where such isolates were rare and transient.
Taxonomic Expansion: While some species (e.g., P. fluorescens, P. putida) have been previously reported in CF, this work identifies several other species in this population for the first time.
Microbiota Characterization: The findings suggest that CFTR modulation induces substantial changes in the airway microenvironment, leading to alterations in the microbial community structure that favor the detection of diverse NAPs.

Significance and Claims
The paper posits that the increased detection of NAPs is likely a reflection of ETI-induced changes in the airway microenvironment rather than necessarily indicating a new pathogenic threat. The authors emphasize that the clinical significance of these isolates remains unclear and that no specific management guidelines currently exist for NAPs in CF. Consequently, the study advocates for careful longitudinal monitoring of both microbiological findings and clinical status to avoid unnecessary antibiotic treatments in clinically stable patients. The authors conclude that further research is required to determine the clinical relevance of these emerging species and to guide future management strategies.

Technical Summary: Increased Frequency of Non-Aeruginosa Pseudomonas Species Post-ETI Therapy

More like this